TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL

Details

Instance of

clinical trial

Start time

20 May 2013

End time

20 May 2023

Main subject

methotrexate, leukemia

clinical trial phase

phase II clinical trial, phase III clinical trial

minimum age

18

number of participants

42

research intervention

thalidomide, prednisone, methotrexate

research site

Henan Cancer Hospital, Jilin University of Chemical Technology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin First Central Hospital

research subject recruitment status

recruiting

study type

interventional study

title

The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China